The results showed that, regardless of age, sex, smoking, presence of hypertension, diabetes, coronary heart disease, history of DVT, eGFR level, urinary protein level, hsCRP level, and renal pathology combined with segmental sclerosis lesions, the baseline value of serum PLA2R antibody titer had a consistent effect on the end point events, and its increase was an independent risk factor affecting the occurrence of the end point events (Table 4). This evidence concerns the gene PLA2R1 and coronary artery disorder.